Medochemie (Far East) Co., Ltd.
Medochemie (Far East) Co., Ltd., headquartered in Cyprus, is a prominent player in the pharmaceutical industry, specialising in the development, manufacturing, and distribution of high-quality generic medicines. Founded in 1976, the company has established a strong presence across the Far East, with operations extending to various key markets. Medochemie is renowned for its extensive portfolio of products, which includes a wide range of therapeutic areas such as cardiovascular, anti-infective, and central nervous system medications. The company’s commitment to quality and innovation sets it apart, ensuring that its offerings meet stringent international standards. With a focus on accessibility and affordability, Medochemie has achieved significant market penetration, making it a trusted name among healthcare professionals and patients alike. Its dedication to excellence and continuous improvement has solidified its position as a leader in the pharmaceutical sector.
DitchCarbon Score
How does Medochemie (Far East) Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medochemie (Far East) Co., Ltd.'s score of 2 is lower than 51% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Medochemie (Far East) Co., Ltd.'s reported carbon emissions
Medochemie (Far East) Co., Ltd., headquartered in Cyprus, has made significant commitments towards reducing its carbon emissions, although specific emissions data for the most recent year is currently unavailable. The company has committed to achieving net-zero emissions across all scopes by 2050, with a starting point in 2023. This long-term target aligns with industry standards and reflects a proactive approach to climate action within the pharmaceuticals, biotechnology, and life sciences sector. As part of its climate strategy, Medochemie is actively engaged in the Science Based Targets initiative (SBTi), demonstrating its commitment to scientifically grounded emissions reduction pathways. While no specific near-term reduction targets have been outlined, the company's commitment to net-zero emissions indicates a comprehensive strategy to address its carbon footprint. Overall, Medochemie's climate commitments position it as a responsible player in the industry, aiming to contribute positively to global climate goals while navigating the challenges of emissions management.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medochemie (Far East) Co., Ltd. is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
